PE20170302A1 - Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington - Google Patents
Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntingtonInfo
- Publication number
- PE20170302A1 PE20170302A1 PE2016002253A PE2016002253A PE20170302A1 PE 20170302 A1 PE20170302 A1 PE 20170302A1 PE 2016002253 A PE2016002253 A PE 2016002253A PE 2016002253 A PE2016002253 A PE 2016002253A PE 20170302 A1 PE20170302 A1 PE 20170302A1
- Authority
- PE
- Peru
- Prior art keywords
- pridopidine
- treatment
- high doses
- huntington disease
- huntington
- Prior art date
Links
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 3
- 229950003764 pridopidine Drugs 0.000 title abstract 3
- 208000023105 Huntington disease Diseases 0.000 title abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837928P | 2013-06-21 | 2013-06-21 | |
| US201361877832P | 2013-09-13 | 2013-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170302A1 true PE20170302A1 (es) | 2017-03-31 |
Family
ID=52105289
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002618A PE20160195A1 (es) | 2013-06-21 | 2014-06-19 | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| PE2016002253A PE20170302A1 (es) | 2013-06-21 | 2014-06-19 | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002618A PE20160195A1 (es) | 2013-06-21 | 2014-06-19 | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10322119B2 (enExample) |
| EP (1) | EP3010506B1 (enExample) |
| JP (1) | JP2016523862A (enExample) |
| KR (1) | KR102316933B1 (enExample) |
| CN (1) | CN105592848A (enExample) |
| AU (1) | AU2014281414A1 (enExample) |
| BR (1) | BR112015029918A2 (enExample) |
| CA (1) | CA2913781C (enExample) |
| CL (1) | CL2015003690A1 (enExample) |
| DK (1) | DK3010506T3 (enExample) |
| EA (1) | EA201690069A1 (enExample) |
| ES (1) | ES2879631T3 (enExample) |
| HK (1) | HK1221646A1 (enExample) |
| HU (1) | HUE054783T2 (enExample) |
| IL (1) | IL242804B (enExample) |
| MX (1) | MX384234B (enExample) |
| PE (2) | PE20160195A1 (enExample) |
| PH (1) | PH12015502691A1 (enExample) |
| PL (1) | PL3010506T3 (enExample) |
| SG (1) | SG11201509729YA (enExample) |
| TW (1) | TW201529069A (enExample) |
| UA (1) | UA122999C2 (enExample) |
| UY (1) | UY35624A (enExample) |
| WO (1) | WO2014205229A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| HUE058288T2 (hu) * | 2014-01-22 | 2022-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin módosított hatóanyag-leadású készítményei |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3590512A1 (en) | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| CA2993183A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| PL3419622T3 (pl) | 2016-02-24 | 2024-07-08 | Prilenia Neurotherapeutics Ltd. | Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny |
| JP6912574B2 (ja) * | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
| BR112019003731A2 (pt) * | 2016-08-24 | 2019-07-16 | Prilenia Therapeutics Dev Ltd | aplicação de pridopidina para tratamento de distonias |
| JP2019529411A (ja) | 2016-09-15 | 2019-10-17 | プリレニア ニューロセラピューティクス リミテッド | 不安症およびうつ病の治療のためのプリドピジンの使用 |
| ES2986807T3 (es) | 2016-09-16 | 2024-11-12 | Prilenia Neurotherapeutics Ltd | Pridopidina para su uso en el tratamiento del síndrome de Rett |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| EP3570940B1 (en) | 2017-01-20 | 2023-12-13 | Prilenia Neurotherapeutics Ltd. | Pridopidine for use in the treatment of fragile x syndrome |
| EA202090510A1 (ru) | 2017-08-14 | 2020-06-08 | Приления Ньюротерапьютикс Лтд. | Способ лечения бокового амиотрофического склероза придопидином |
| WO2019046568A1 (en) | 2017-08-30 | 2019-03-07 | Teva Pharmaceuticals International Gmbh | DOSAGE FORMS WITH HIGH CONCENTRATION OF PRIDOPIDINE |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| MX383462B (es) | 2017-09-08 | 2025-03-14 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos |
| JP2022521457A (ja) * | 2019-01-31 | 2022-04-08 | エフ．ホフマン－ラ ロシュ アーゲー | ハンチントン病の進行度の評価方法 |
| US12357624B2 (en) | 2019-02-04 | 2025-07-15 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism |
| JP7436524B2 (ja) * | 2019-06-12 | 2024-02-21 | プリレニア ニューロセラピューティクス リミテッド | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 |
| EP4030993A4 (en) * | 2019-09-17 | 2023-10-25 | F. Hoffmann-La Roche AG | Improvements in personalized healthcare for patients with movement disorders |
| WO2022094565A1 (en) * | 2020-10-28 | 2022-05-05 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| EP1713486A4 (en) | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
| AU2005293754B2 (en) | 2004-10-13 | 2011-07-21 | Teva Pharmaceuticals International Gmbh | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| BRPI0810161A2 (pt) | 2007-04-12 | 2014-12-30 | Nsab Af Neurosearch Sweden Ab | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto |
| US8669048B2 (en) | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| EP2753603B1 (en) | 2011-09-07 | 2017-06-21 | Teva Pharmaceuticals International GmbH | Polymorphic form of pridopidine hydrochloride |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| EA027748B1 (ru) | 2012-04-04 | 2017-08-31 | Тева Фармасьютикалз Интернэшнл Гмбх | Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения |
| CA2884260A1 (en) | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| AU2013323131A1 (en) | 2012-09-27 | 2015-05-07 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| HUE058288T2 (hu) | 2014-01-22 | 2022-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin módosított hatóanyag-leadású készítményei |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP3590512A1 (en) | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| BR112019003731A2 (pt) | 2016-08-24 | 2019-07-16 | Prilenia Therapeutics Dev Ltd | aplicação de pridopidina para tratamento de distonias |
| JP6912574B2 (ja) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
| JP2019529411A (ja) | 2016-09-15 | 2019-10-17 | プリレニア ニューロセラピューティクス リミテッド | 不安症およびうつ病の治療のためのプリドピジンの使用 |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| ES2986807T3 (es) | 2016-09-16 | 2024-11-12 | Prilenia Neurotherapeutics Ltd | Pridopidina para su uso en el tratamiento del síndrome de Rett |
-
2014
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en not_active Ceased
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active Active
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 HK HK16109788.9A patent/HK1221646A1/zh unknown
- 2014-06-19 MX MX2015017307A patent/MX384234B/es unknown
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20160195A1 (es) | 2016-05-14 |
| HK1221646A1 (zh) | 2017-06-09 |
| EP3010506A4 (en) | 2017-02-08 |
| MX2015017307A (es) | 2016-08-03 |
| CA2913781A1 (en) | 2014-12-24 |
| US20140378508A1 (en) | 2014-12-25 |
| EP3010506A1 (en) | 2016-04-27 |
| WO2014205229A8 (en) | 2015-04-09 |
| IL242804B (en) | 2022-02-01 |
| TW201529069A (zh) | 2015-08-01 |
| KR20160055122A (ko) | 2016-05-17 |
| UY35624A (es) | 2015-01-30 |
| SG11201509729YA (en) | 2015-12-30 |
| JP2016523862A (ja) | 2016-08-12 |
| EA201690069A1 (ru) | 2016-06-30 |
| EP3010506B1 (en) | 2021-05-12 |
| UA122999C2 (uk) | 2021-02-03 |
| ES2879631T3 (es) | 2021-11-22 |
| AU2014281414A1 (en) | 2016-01-21 |
| PL3010506T3 (pl) | 2021-11-02 |
| BR112015029918A2 (pt) | 2017-07-25 |
| CN105592848A (zh) | 2016-05-18 |
| KR102316933B1 (ko) | 2021-10-26 |
| DK3010506T3 (da) | 2021-07-12 |
| CA2913781C (en) | 2022-05-10 |
| MX384234B (es) | 2025-03-14 |
| PH12015502691A1 (en) | 2016-03-14 |
| HUE054783T2 (hu) | 2021-09-28 |
| US10322119B2 (en) | 2019-06-18 |
| CL2015003690A1 (es) | 2016-10-28 |
| WO2014205229A1 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| CL2016001874A1 (es) | Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras. | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| JP2015532296A5 (enExample) | ||
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| CL2013002810A1 (es) | Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. | |
| MX344303B (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| CL2012003152A1 (es) | Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada. | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| MX2016007376A (es) | Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa. | |
| MX2022002356A (es) | Forma de dosificacion oral solida que comprende naproxeno y vitamina b12. | |
| RU2010134265A (ru) | Способ лечения диспепсии у телят | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico | |
| MX385725B (es) | Composición farmacéutica que comprende sumatriptán para tratamiento de migraña. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |